CA2231195A1 - Sustained release matrix for high-dose insoluble drugs - Google Patents

Sustained release matrix for high-dose insoluble drugs

Info

Publication number
CA2231195A1
CA2231195A1 CA002231195A CA2231195A CA2231195A1 CA 2231195 A1 CA2231195 A1 CA 2231195A1 CA 002231195 A CA002231195 A CA 002231195A CA 2231195 A CA2231195 A CA 2231195A CA 2231195 A1 CA2231195 A1 CA 2231195A1
Authority
CA
Canada
Prior art keywords
sustained release
insoluble drugs
release matrix
dose
dose insoluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002231195A
Other languages
French (fr)
Other versions
CA2231195C (en
Inventor
Anand R. Baichwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penwest Pharmaceuticals Co
Original Assignee
Edward Mendell Co., Inc.
Anand R. Baichwal
Penwest Pharmaceuticals Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edward Mendell Co., Inc., Anand R. Baichwal, Penwest Pharmaceuticals Co. filed Critical Edward Mendell Co., Inc.
Publication of CA2231195A1 publication Critical patent/CA2231195A1/en
Application granted granted Critical
Publication of CA2231195C publication Critical patent/CA2231195C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Sustained release dosage forms of high dose insoluble drugs such as ibuprofen and methods for their manufacture are disclosed.
CA002231195A 1996-07-08 1997-07-08 Sustained release matrix for high-dose insoluble drugs Expired - Fee Related CA2231195C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2133596P 1996-07-08 1996-07-08
US60/021,335 1996-07-08
PCT/US1997/013331 WO1998001117A1 (en) 1996-07-08 1997-07-08 Sustained release matrix for high-dose insoluble drugs

Publications (2)

Publication Number Publication Date
CA2231195A1 true CA2231195A1 (en) 1998-01-15
CA2231195C CA2231195C (en) 2003-01-21

Family

ID=21803631

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002231195A Expired - Fee Related CA2231195C (en) 1996-07-08 1997-07-08 Sustained release matrix for high-dose insoluble drugs

Country Status (12)

Country Link
US (4) US6093420A (en)
EP (1) EP0859603B1 (en)
JP (1) JP3148256B2 (en)
KR (1) KR100321489B1 (en)
AT (1) ATE417604T1 (en)
AU (1) AU695734B2 (en)
CA (1) CA2231195C (en)
DE (1) DE69739165D1 (en)
ES (1) ES2322405T3 (en)
IL (1) IL123505A (en)
MX (1) MX9801835A (en)
WO (1) WO1998001117A1 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
ES2322405T3 (en) * 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. CONTROLLED LIBERATION MATRIX FOR INSOLUBLE DRUGS IN HIGH DOSE.
WO1999009988A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AU740586B2 (en) * 1998-04-07 2001-11-08 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
IL143375A0 (en) * 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
US20050037073A1 (en) * 2000-01-13 2005-02-17 Alpharx Inc. Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
HUP0501071A3 (en) * 2001-03-13 2007-06-28 Penwest Pharmaceutical Co Chronotherapeutic dosage forms
DK1404331T3 (en) * 2001-07-06 2008-01-28 Penwest Pharmaceuticals Co Sustained release formulations of oxymorphone
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2452874A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US6705028B2 (en) * 2001-09-12 2004-03-16 Honda Giken Kogyo Kabushiki Kaisha Self-propelled snowplow vehicle
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
PE20030527A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
PT1471887E (en) 2002-02-04 2010-07-16 Elan Pharma Int Ltd Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
ATE343376T1 (en) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
MXPA04009701A (en) * 2002-04-05 2005-05-27 Penwest Pharmaceuticals Co Sustained release metoprolol formulations.
US20030232097A1 (en) * 2002-06-17 2003-12-18 Strides Inc. Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
AU2003261298A1 (en) 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
CN1767815A (en) * 2003-03-31 2006-05-03 阿尔萨公司 Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
MXPA06003100A (en) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Delayed released dosage forms.
MXPA06003101A (en) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
WO2005037264A1 (en) * 2003-10-17 2005-04-28 Medrx Co., Ltd. Jelly preparation containing biguanide medicine
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
CN101212958A (en) * 2005-06-29 2008-07-02 万能药生物有限公司 Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
RU2403013C2 (en) * 2005-12-16 2010-11-10 Ханми Фарм. Ко., Лтд. Solid dispersion containing active component with low fusion temperature, and oral tablet containing it
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
GB2438287A (en) * 2006-05-19 2007-11-21 Norbrook Lab Ltd Stable aqueous suspension
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
US9023381B2 (en) * 2007-01-26 2015-05-05 Michelle Chow Enhanced medicinal delivery system processes and products thereby especially useful for children
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
KR101616246B1 (en) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 Pharmaceutical dosage form
US20110287091A1 (en) * 2009-01-22 2011-11-24 Abbot Healthcare Private Limited Chronotherapeutic pharmaceutical composition
MX2012000317A (en) 2009-07-22 2012-02-08 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form.
RU2015138422A (en) 2009-07-22 2018-12-25 Грюненталь Гмбх STABLE DURING OXIDATION, STRONG-BREAKED DOSAGE FORM
ES2487244T3 (en) 2010-09-02 2014-08-20 Grünenthal GmbH Handling resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
AU2012292418B2 (en) 2011-07-29 2017-02-16 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX356421B (en) 2012-02-28 2018-05-29 Gruenenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer.
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
CN104394851B (en) 2012-04-18 2017-12-01 格吕伦塔尔有限公司 Anti-distort and anti-agent amount are come down in torrents pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096438A1 (en) 2013-05-29 2015-12-30 Gruenenthal Gmbh DOSAGE FORM RESISTANT TO INDEBITED USE WITH BIMODAL RELEASE PROFILE, PROCESS
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (en) 2013-07-12 2019-12-31 Gruenenthal Gmbh tamper-resistant dosage form containing ethylene vinyl acetate polymer
CN105934241B (en) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 Preparation of powdered pharmaceutical composition by cryogenic grinding
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (en) * 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Multiparticulates protected against ethanol overdose
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
KR20220140711A (en) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (en) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4- (2'-nitrophenyl) -2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridine
SU432703A3 (en) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
DE2714065A1 (en) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh INSTILLATION PREPARATION
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3033919A1 (en) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen SOLID PHARMACEUTICAL PREPARATIONS CONTAINING NIFEDIPINE AND METHOD FOR THE PRODUCTION THEREOF
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
JPS5846019A (en) * 1981-09-14 1983-03-17 Kanebo Ltd Nifedipine preparation with prolonged action
JPS59101423A (en) * 1982-12-02 1984-06-12 Takada Seiyaku Kk Novel solid pharmaceutical preparation of nifedipine
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
DE3318649A1 (en) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen TWO-PHASE FORMULATION
DE3320582A1 (en) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach METHODS OF PREPARATION WITH GLIQUIDONE AND METHOD FOR THE PRODUCTION THEREOF
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
JPS60139688A (en) * 1983-12-28 1985-07-24 Tokyo Tanabe Co Ltd Amorphous dihydropyridine powder pharmaceutical
DE3400106A1 (en) * 1984-01-04 1985-07-11 Klaus-Dieter Dr. 3550 Marburg Bremecker Pharmaceutical compositions with controlled release of medicinal substance
KR850700212A (en) * 1984-03-21 1985-12-26 죠지 드모트 Sustained Release Pharmaceutical Wexel
NL194389C (en) * 1984-06-14 2002-03-04 Novartis Ag Process for preparing a solid dispersion of a pharmaceutically active agent that has low water solubility in a solid matrix of a water-soluble polyalkylene glycol as a carrier.
DE3438830A1 (en) * 1984-10-23 1986-04-30 Rentschler Arzneimittel PHARMACEUTICAL FORM CONTAINING NIFEDIPIN AND METHOD FOR THE PRODUCTION THEREOF
EP0184910B1 (en) * 1984-11-15 1992-09-30 Hercon Laboratories Corporation Device for controlled release drug delivery
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
IT1187751B (en) * 1985-10-15 1987-12-23 Eurand Spa PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
GB8608818D0 (en) * 1986-04-11 1986-05-14 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
SE8601624D0 (en) * 1986-04-11 1986-04-11 Haessle Ab NEW PHARMACEUTICAL PREPARATIONS
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3636123A1 (en) * 1986-10-23 1988-05-05 Rentschler Arzneimittel ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE
ES2040697T3 (en) * 1986-12-18 1993-11-01 Kurt H. Prof. Dr. Bauer NIFEDIPINE CONCENTRATE STABILIZED AGAINST THE INFLUENCE OF LIGHT, AND PROCEDURE FOR ITS PREPARATION.
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US5288500A (en) * 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
KR880012221A (en) * 1987-04-13 1988-11-26 사노 가즈오 Pharmaceutical compositions containing esters or amides as active ingredients
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
DE3720757A1 (en) * 1987-06-24 1989-01-05 Bayer Ag DHP COAT TABLET
FR2618073B1 (en) * 1987-07-16 1990-09-07 Pf Medicament HYDROPHILIC MATRIX-TYPE TABLETS BASED ON SALBUTAMOL AND THEIR PREPARATION METHOD
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
GB8722306D0 (en) * 1987-09-22 1987-10-28 Aps Research Ltd Sustained-release formulation
SE8703881D0 (en) * 1987-10-08 1987-10-08 Haessle Ab NEW PHARMACEUTICAL PREPARATION
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
JP2670680B2 (en) * 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
DE68915494T2 (en) * 1988-03-09 1995-01-05 Snow Brand Milk Products Co Ltd PREPARATION WITH DELAYED RELEASE BY USING ALGINATES.
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
JP2528706B2 (en) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 Pharmaceutical composition of dihydropyridine compound
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
IE66933B1 (en) 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
IT1246188B (en) * 1990-07-27 1994-11-16 Resa Farma PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING INCREASED SPEED OF DISSOLUTION OF THE ACTIVE SUBSTANCE AND COMPOSITIONS OBTAINED.
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US5292534A (en) 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
IT1255792B (en) * 1992-08-05 1995-11-16 Bayer Italia Spa PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF DIHYDROPYRIDINS IN THE FORM OF DRINK
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
BE1006990A5 (en) * 1993-04-22 1995-02-07 Univ Gent METHOD AND COMPOSITION TO MAKE AN ACTIVE INGREDIENT IN A solid dosage form.
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
CA2205442C (en) * 1994-12-01 2003-01-21 David R. Friend Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
ES2322405T3 (en) * 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. CONTROLLED LIBERATION MATRIX FOR INSOLUBLE DRUGS IN HIGH DOSE.
US5845563A (en) * 1997-01-10 1998-12-08 Sunbeam Products, Inc. Rotisserie cooker
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation

Also Published As

Publication number Publication date
US6689386B2 (en) 2004-02-10
US6093420A (en) 2000-07-25
KR100321489B1 (en) 2002-10-09
IL123505A (en) 2004-12-15
US6245355B1 (en) 2001-06-12
CA2231195C (en) 2003-01-21
EP0859603A1 (en) 1998-08-26
US20010021392A1 (en) 2001-09-13
ATE417604T1 (en) 2009-01-15
EP0859603A4 (en) 2006-05-24
AU3818397A (en) 1998-02-02
JP3148256B2 (en) 2001-03-19
MX9801835A (en) 1998-08-30
ES2322405T3 (en) 2009-06-19
AU695734B2 (en) 1998-08-20
EP0859603B1 (en) 2008-12-17
DE69739165D1 (en) 2009-01-29
JPH10511407A (en) 1998-11-04
US20040121012A1 (en) 2004-06-24
WO1998001117A1 (en) 1998-01-15
KR19990044486A (en) 1999-06-25
IL123505A0 (en) 1998-10-30

Similar Documents

Publication Publication Date Title
CA2231195A1 (en) Sustained release matrix for high-dose insoluble drugs
FI961996A (en) Sustained-release preparations for 24-hour release of metoprolol
CA2131350A1 (en) Sustained release drug formulation containing a tramadol salt
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
EP1245231A3 (en) Pharmaceutical formulations containing darifenacin
EP1110542A3 (en) Once-a-day metoprolol oral dosage form
AU7305594A (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation
CA2199778A1 (en) Extended release formulation of venlafaxine
AU5335698A (en) Pharmaceutical formulations with delayed drug release
AU7239996A (en) Inhibition of tumor necrosis factor alpha
CA2326198A1 (en) Cosolvent formulations
CA2325360A1 (en) Compositions comprising osteoprotegerin for the prevention and treatment of cardiovascular diseases
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
AU2773597A (en) Pharmaceutical compositions for the sustained release of insoluble active principles
CA2354039A1 (en) Pharmaceutical formulations in hydroxypropylmethylcellulose capsules
IL136142A0 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
AU5139596A (en) Pharmaceutical matrix pellets, tablets and composition for the preparation thereof
CA2236256A1 (en) A pharmaceutical composition for the treatment of autoimmune diseases
CA2281474A1 (en) Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof
AU6037494A (en) Use of active substances in the therapy of certain diseases, process for preparing a pharmaceutical composition for that purpose and pharmaceutical compositions thus prepared
AU5304998A (en) Sustained release pharmaceutical tablets with tramadol base and their preparation
GB9507677D0 (en) Pharmaceutical formulation and dose
CA2249637A1 (en) Uniform drug delivery therapy
AU9737198A (en) Pharmaceutical composition comprising 3,4-diarylchromans in low dose

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150708